Characterization of Leishmania infantum thiol-dependent reductase 1 and evaluation of its potential to induce immune protection

Parasite Immunology

Volumn 34, Issue 6, 2012, Pages 345-350

  Silva, A M ^a,b,c   Tavares, J ^a,b   Silvestre, R ^a   Ouaissi, A ^d   Coombs, G H ^c   Cordeiro da Silva, A ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^d INSERM   (France)

Author keywords

Leishmania infantum; TDR1; Visceral leishmaniasis

Indexed keywords

OXIDOREDUCTASE; PROTEIN DISULFIDE REDUCTASE (GLUTATHIONE); PROTOZOAL PROTEIN; RECOMBINANT PROTEIN; RECOMBINANT THIOL DEPENDENT REDUCTASE 1; THIOL DEPENDENT REDUCTASE 1; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOSOL; HOST PARASITE INTERACTION; IMMUNE RESPONSE; IMMUNITY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LEISHMANIA INFANTUM; LEISHMANIASIS; MOUSE; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SEQUENCE HOMOLOGY; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; OXIDOREDUCTASES; PARASITE LOAD; PROTOZOAN VACCINES; SPLEEN; VACCINES, SYNTHETIC;

LEISHMANIA INFANTUM; MAMMALIA; MURINAE; MUS; TRYPANOSOMA CRUZI;

EID: 84860914599     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2012.01361.x     Document Type: Article

References (23)

1. Kedzierski L. Leishmaniasis vaccine: where are we today? J Glob Infect Dis 2010; 2: 177-185.
2. Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10years. Clin Microbiol Rev 2008; 21: 334-359.
3. Croft SL, Sundar S & Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19: 111-126.
4. Gangneux JP, Sulahian A, Honore S, Meneceur P, Derouin F & Garin YJ. Evidence for determining parasitic factors in addition to host genetics and immune status in the outcome of murine Leishmania infantum visceral leishmaniasis. Parasite Immunol 2000; 22: 515-519.
5. Kaye PM & Aebischer T. Visceral leishmaniasis: immunology and prospects for a vaccine. Clin Microbiol Infect 2011; 17: 1462-1470.
6. Chakravarty J, Kumar S, Trivedi S, et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 2011; 29: 3531-3537.
7. Coler RN, Goto Y, Bogatzki L, Raman V & Reed SG. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect Immun 2007; 75: 4648-4654.
8. Denton H, McGregor JC & Coombs GH. Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1. Biochem J 2004; 381: 405-412.
9. Muller S, Liebau E, Walter RD & Krauth-Siegel RL. Thiol-based redox metabolism of protozoan parasites. Trends Parasitol 2003; 19: 320-328.
10. Ouaissi A, Guevara-Espinoza A, Chabe F, Gomez-Corvera R & Taibi A. A novel and basic mechanism of immunosuppression in Chagas' disease: Trypanosoma cruzi releases in vitro and in vivo a protein which induces T cell unresponsiveness through specific interaction with cysteine and glutathione. Immunol Lett 1995; 48: 221-224.
11. Garzon E, Borges MC, Cordeiro-da-Silva A, et al. Trypanosoma cruzi carrying a targeted deletion of a Tc52 protein-encoding allele elicits attenuated Chagas' disease in mice. Immunol Lett 2003; 89: 67-80.
12. Moutiez M, Quemeneur E, Sergheraert C, Lucas V, Tartar A & Davioud-Charvet E. Glutathione-dependent activities of Trypanosoma cruzi p52 makes it a new member of the thiol:disulphide oxidoreductase family. Biochem J 1997; 322: 43-48.
13. Sereno D & Lemesre JL. Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob Agents Chemother 1997; 41: 972-976.
14. Hausler T, Stierhof YD, Wirtz E & Clayton C. Import of a DHFR hybrid protein into glycosomes in vivo is not inhibited by the folate-analogue aminopterin. J Cell Biol 1996; 132: 311-324.
15. McConville MJ, Mullin KA, Ilgoutz SC & Teasdale RD. Secretory pathway of trypanosomatid parasites. Microbiol Mol Biol Rev 2002; 66: 122-154.
16. Silverman JM, Clos J, de'Oliveira CC, et al. An exosome-based secretion pathway is responsible for protein export from Leishmania and communication with macrophages. J Cell Sci 2010; 123: 842-852.
17. Cuervo P, De Jesus JB, Saboia-Vahia L, Mendonca-Lima L, Domont GB & Cupolillo E. Proteomic characterization of the released/secreted proteins of Leishmania (Viannia) braziliensis promastigotes. J Proteomics 2009; 73: 79-92.
18. Silverman JM, Chan SK, Robinson DP, et al. Proteomic analysis of the secretome of Leishmania donovani. Genome Biol 2008; 9: R35.
19. Santarem N, Silvestre R, Tavares J, et al. Immune response regulation by leishmania secreted and nonsecreted antigens. J Biomed Biotechnol 2007; 2007: 85154.
20. Pan JL & Bardwell JC. The origami of thioredoxin-like folds. Protein Sci 2006; 15: 2217-2227.
21. Ivens AC, Peacock CS, Worthey EA, et al. The genome of the kinetoplastid parasite, Leishmania major. Science 2005; 309: 436-442.
22. Buffet PA, Sulahian A, Garin YJ, Nassar N & Derouin F. Culture microtitration: a sensitive method for quantifying Leishmania infantum in tissues of infected mice. Antimicrob Agents Chemother 1995; 39: 2167-2168.
23. Chu N, Thomas BN, Patel SR & Buxbaum LU. IgG1 is pathogenic in Leishmania mexicana infection. J Immunol 2010; 185: 6939-6946.